Feature|Videos|May 19, 2026

Integrated Solutions for Complex Drug Development

Key Takeaways

  • Understand the strategic evolution of Pace® Life Sciences as they celebrate 20 years of business.
  • Learn how to make investment decisions around emerging technologies.
SHOW MORE

The evolution of Pace® Life Sciences from an analytical services firm to a full-service CDMO supporting the drug development lifecycle.

Sponsored by Pace® Life Sciences

As drug modalities grow increasingly complex—spanning biologics, cell and gene therapies, antibody drug conjugates, and combination formats—CDMOs are pivoting their tactics to support these modalities. Frank Tagliaferri, PhD, Chief Scientific Officer at Pace® Life Sciences, explains how Pace Analytical expanded into a broad-based CDMO serving clients across the drug development lifecycle, from late discovery through commercial products. Growth came through a combination of targeted acquisitions and organic investment, adding capabilities such as clinical trial manufacturing, regulatory consulting, and advanced analytical testing across multiple locations. This led to the creation of a platform model that focuses on anticipating client needs and accelerating access to data to support faster decision-making throughout the drug development process.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.